|
KMID : 1812020180240040577
|
|
Journal of Neurogastroenterology and Motility
2018 Volume.24 No. 4 p.577 ~ p.583
|
|
|
Pathophysiology of Potassium-competitive Acid Blocker?refractory Gastroesophageal Reflux and the Potential of Potassium-competitive Acid Blocker Test
|
|
|
|
|
Abstract
|
|
|
Background/Aims: Potassium-competitive acid blockers are expected to be the next generation of drugs for the treatment of diseases caused by gastric acid. In 2015, vonoprazan fumarate, a novel potassium-competitive acid blocker, was approved by the Japanese health insurance system. Since its approval, patients refractory to vonoprazan can be encountered in clinical settings. We designed this study to clarify the pathophysiology of gastroesophageal reflux disease refractory to vonoprazan.
Methods: In this retrospective study, we involved patients who had refractory symptoms after administration of standard-dose proton pump inhibitors or vonoprazan and underwent diagnostic testing with esophageal high-resolution manometry and 24-hour multichannel intraluminal impedance and pH monitoring while using proton pump inhibitors or vonoprazan. Patients were diagnosed based on the Rome IV criteria for functional gastrointestinal disorders and diagnostic test results.
Results: Twenty-seven patients were analyzed during this study. Gastric pH ≥ 4 was sustained for a longer period of time, and the esophageal acid exposure time and number of acid reflux events were shorter in the vonoprazan group than in the proton pump inhibitor group. The percentage of patients diagnosed with acidic gastroesophageal reflux disease in the vonoprazan group was lower than that in the proton pump inhibitor group.
Conclusions: Intra-gastric pH and acid reflux were strongly suppressed by 20-mg vonoprazan. When patients with gastroesophageal reflux disease present symptoms after administration of 20-mg vonoprazan, the possibility of pathophysiologies other than acid reflux should be considered.
|
|
|
KEYWORD
|
|
|
Esophageal motility disorders, Esophageal pH monitoring, Gastroesophageal reflux, Proton pump inhibitors
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
   
|